Healthcare / BiotechnologyHKSE
$18.17
-0.33 (-1.78%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $304.0M · quality 58.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.1B
P/E
14.5x
↓EV/EBITDA
4.7x
↓ROE
4.6%
↑Gross Margin
70.0%
↑Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.2%
FCF CAGR
—
FCF margin
12.4%
FCF / Net income
1.21x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.45B · net income $251.0M · FCF $304.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.45B | $2.45B | $2.68B | $2.63B | $2.10B |
| Net Income | $251.0M | $251.0M | $420.4M | $416.1M | $180.5M |
| EBITDA | $464.9M | $464.9M | $689.4M | $713.4M | $447.5M |
| EPS | 1.08 | 1.08 | 1.80 | 1.74 | 0.74 |
| Gross Margin | 70.0% | 70.0% | 69.7% | 70.3% | 68.8% |
| Operating Margin | 13.0% | 13.0% | 16.7% | 16.6% | 10.5% |
| Net Margin | 10.3% | 10.3% | 15.7% | 15.8% | 8.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.08 | 0.07 | 0.02 |
| Current Ratio | 3.73 | 3.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $304.0M | $304.0M | $285.1M | $367.2M | $-85.9M |
| Returns | |||||
| ROE | 4.6% | 4.6% | 7.5% | 7.4% | 3.3% |
| Valuation | |||||
| P/E | 14.54 | 14.54 | 14.22 | 22.03 | 56.34 |
| EV/EBITDA | 4.66 | 4.66 | 5.49 | 9.58 | 17.31 |
| P/B | 0.78 | 0.78 | 1.07 | 1.62 | 1.84 |
| Growth & Yield | |||||
| Revenue Growth | -8.7% | -8.7% | 1.7% | 25.3% | — |
| EPS Growth | -40.0% | -40.0% | 3.3% | 134.6% | — |
| Dividend Yield | 6.1% | 6.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
14.3%
EPS terminal req.
$1.61
Spread vs growth
-54.3%
5Y implied EPS CAGR
12.6%
EPS terminal req.
$1.95
Spread vs growth
-52.6%
10Y implied EPS CAGR
11.3%
EPS terminal req.
$3.14
Spread vs growth
-51.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-27.2%
Start / end P/E
15.1x → 16.8x
EPS bridge
1.80 → 1.08
Residual
-4.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.